Category: ‘Clinical Trials and Studies’
Neuroplast Announces Successful Clinical Phase I Trial with Neuro-Cells Stem Cell Treatment for Traumatic Spinal Cord Injury
Posted on November 11th, 2021
Dutch biotech company, Neuroplast, and the Hospital Nacional de Parapléjicos de Toledo in Spain have announced positive clinical Phase I results after analysis of ten patients suffering from traumatic spinal cord injury (TSCI), with data demonstrating that its investigational stem cell treatment, Neuro-Cells, appears to be safe and well tolerated, without product-related adverse events.
The treatment uses the patient’s own stem cells to prevent further loss of function after sustaining TSCI, in an effort to limit loss of mobility and independence of otherwise life-long impairment.
NeuroRegen Scaffold Transplantation Brings Hope to Spinal Cord Injury Patients
Posted on September 10th, 2021
A joint group of Chinese scientists has recently confirmed the safety and preliminary effective of NeuroRegen Scaffold transplantation for spinal cord injury repair. Results were published in Science China Life Sciences.
Read more of NeuroRegen Scaffold Transplantation Brings Hope to Spinal Cord Injury Patients »
Transforming Thoughts to Movement Offers New Hope for Spinal Cord Injury Patients
Posted on November 5th, 2019
A team of researchers at The Miami Project to Cure Paralysis and the Miller School of Medicine is using a brain-machine interface to help restore function in paralysis patients after spinal cord injury.
Read more of Transforming Thoughts to Movement Offers New Hope for Spinal Cord Injury Patients »
Experimental Spinal Cord Treatment Helps Texas Man Regain Some Motion After Paralyzing Accident
Posted on May 31st, 2019
Kent Stephenson is on a treadmill, working to put one foot in front of the other as a team of trainers helps guide his legs. There’s a harness holding him upright, but Stephenson is, in a sense, walking again — 10 years after a motocross accident left him paralyzed.
InVivo Therapeutics Announces Enrollment of INSPIRE 2.0 Study
Posted on May 29th, 2019
InVivo Therapeutics Announces Enrollment of First Two Patients into the INSPIRE 2.0 Study for the Treatment of Acute Spinal Cord Injury
InVivo Therapeutics Holdings Corp. today announced that the first two patients have been enrolled into The INSPIRE 2.0 Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury).
Read more of InVivo Therapeutics Announces Enrollment of INSPIRE 2.0 Study »